SCHEMBL2215374

SCHEMBL2215374

Cn1nc(C2CC2)cc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
GRN P28799 1/20 0.50
SORT1 Q99523 1/20 0.50
KCNT1 Q5JUK3 4/20 0.46
PSMB8 P28062 1/20 0.46
PSMB9 P28065 1/20 0.46
PSMB5 P28074 1/20 0.46
PDK1 Q15118 3/20 0.44
PDK2 Q15119 3/20 0.44
CACNA1H O95180 1/20 0.43
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
PKM P14618 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
RAF1 P04049 1/20 0.36
BRAF P15056 1/20 0.36
KCNJ6 P48051 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8031275 0.93 PSMB8 (0.53) KDM4EGRNSORT1KCNT1PSMB8
SCHEMBL11899894 0.93 PSMB8 (0.50) KDM4EGRNSORT1KCNT1PSMB8
SCHEMBL27028206 0.89 KDM4E (0.42) KDM4EGRNSORT1KCNT1PSMB8
SCHEMBL23293556 0.89 KDM4E (0.42) KDM4EGRNSORT1KCNT1PSMB8
SCHEMBL17454397 0.86 PSMB8 (0.46) KDM4EGRNSORT1KCNT1PSMB8
SCHEMBL3065968 0.84 KCNT1 (0.46) KDM4EGRNSORT1KCNT1PSMB8
SCHEMBL4072006 0.84 PSMB8 (0.45) KDM4EGRNSORT1KCNT1PSMB8
SCHEMBL17452576 0.81 PSMB8 (0.49) KDM4EKCNT1PSMB8PSMB9PSMB5
SCHEMBL15273648 0.81 PSMB8 (0.46) KDM4EKCNT1PSMB8PSMB9PSMB5
SCHEMBL19902353 0.81 PSMB8 (0.46) KCNT1PSMB8PSMB9PSMB5PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1720046-A 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related diseases such as dyslipidemia ARENA PHARM INC (US) 2006-01-11 CN claimed
US-20260132111-A1 Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics PROSETTA BIOSCIENCES INC (US) 2026-05-14 US disclosed
US-12459901-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics PROSETTA BIOSCIENCES, INC. (US) 2025-11-04 US disclosed
CN-114206335-B KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2025-03-11 CN disclosed
EP-4446314-A2 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2024-10-16 EP disclosed
CN-118488947-A Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof 劲方医药科技(上海)有限公司 2024-08-13 CN disclosed
EP-4402124-A1 NOVEL HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS Prosetta Biosciences, Inc. (US) 2024-07-24 EP disclosed
EP-3962479-B1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2024-07-24 EP disclosed
US-12017997-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics PROSETTA BIOSCIENCES, INC. (US) 2024-06-25 US disclosed
US-12017997-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics PROSETTA BIOSCIENCES, INC. (US) 2024-06-25 US disclosed
US-20130252961-A1 MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER INC. (US) 2013-09-26 US disclosed
WO-2013132376-A1 MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES PFIZER INC. (US) 2013-09-12 WO disclosed
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-09-13 US disclosed
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-09-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed
US-20110301181-A1 halogen-substituted compounds BAYER CROPSCIENCE AG (DE) 2011-12-08 US disclosed
EP-2352723-A2 HALOGEN-SUBSTITUTED COMPOUNDS USED AS PESTICIDES Bayer CropScience AG (DE) 2011-08-10 EP disclosed
US-20110178063-A1 BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES GLAXO GROUP LIMITED (GB) 2011-07-21 US disclosed
WO-2010051926-A2 NEW HALOGEN-SUBSTITUTED BONDS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2010-05-14 WO disclosed
CN-1720046-A 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related diseases such as dyslipidemia ARENA PHARM INC (US) 2006-01-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178063-A1 BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES PIK3CA, PIK3CD, PI4KA KDM4E 2484/4885GRN 3705/4885SORT1 4581/4885
US-20260132111-A1 Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics NCOR1, HAVCR2, NR3C1 KDM4E 4577/4885GRN 1738/4885SORT1 3975/4885
US-12017997-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics MAVS, SARS1, ZC3HAV1 KDM4E 4045/4885GRN 2800/4885SORT1 3532/4885
US-20130252961-A1 MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES ALK, ETV6, EML4 KDM4E 318/4885GRN 1076/4885SORT1 2830/4885
US-20110301181-A1 halogen-substituted compounds L3MBTL4, QSOX1, L3MBTL3 KDM4E 2403/4885GRN 3116/4885SORT1 4798/4885
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN1B, SCN1A, SCN2B KDM4E 1141/4885GRN 3633/4885SORT1 3698/4885
US-12459901-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics MAVS, SARS1, ZC3HAV1 KDM4E 4045/4885GRN 2800/4885SORT1 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.